Swiss drug makers Lonza and Roche agreed in March to the sale the Vacaville campus in the heart of Solano County’s burgeoning ...

It has shifted commercial manufacturing off Genentech's South San Francisco campus, cut hundreds of jobs, broken up its cancer immunology group and pared programs. The company, which employs about ...

October 09, 2024, 6:27 PM ESTCommercial Real Estate July 18, 2024, 9:37 AM ESTHealth Care March 06, 2024, 2:50 PM ESTHealth Care June 16, 2022, 4:42 PM ESTHealth Care May 18, 2021, 3:28 PM ...

As Election Day 2024 gets closer, STAT’s First Opinion asked executives from leading biotech and pharmaceutical companies to reflect on how their industry is being portrayed in the presidential ...

Roche’s Genentech unit has looked internally for its new chief executive, appointing Ashley Magargee to the role following the departure of Alexander Hardy last month. Magargee has been serving ...

Genentech has received Food and Drug Administration approval for its treatment of certain types of lung, liver, skin and soft ...

A $1.2 billion deal by Swiss biotech firm Lonza to purchase the Vacaville Genentech site from Roche has been finalized, the firm announced Tuesday, securing 750 biotech jobs in Vacaville.

Genentech is paying $850 million upfront for Regor Pharmaceuticals’ portfolio of CDK inhibitors, taking ownership of a breast cancer candidate that has shown signs of single-agent efficacy in ...

--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive topline results from the Phase III REGENCY study of Gazyva ...

Genentech Inc. didn’t need to wait until Thanksgiving for the U.S. FDA to make up its mind. More than a month ahead of its PDUFA date, the agency approved the firm’s first-line breast cancer treatment ...

With Tecentriq Hybreza and Roche/Genentech’s 13 other subcutaneous therapies – available across various diseases – we offer additional administration options to meet the diverse preferences ...

(RTTNews) - Regor Pharmaceuticals USA has entered into a definitive purchase agreement, under which Genentech, a member of the Roche Group, will acquire a portfolio of next-generation CDK ...